Dr. Reddy's Laboratories Limited (RDY)
USD 14.55
(0.48%)
USD 14.55
(0.48%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 12.91 Billion INR | 67.85% |
| 2023 | 7.69 Billion INR | -59.5% |
| 2022 | 18.99 Billion INR | 22.7% |
| 2021 | 15.47 Billion INR | -22.79% |
| 2020 | 20.04 Billion INR | -44.54% |
| 2019 | 36.15 Billion INR | -24.8% |
| 2018 | 48.07 Billion INR | 54.84% |
| 2017 | 31.04 Billion INR | 581.98% |
| 2016 | -6.44 Billion INR | -285.54% |
| 2015 | 3.47 Billion INR | -69.02% |
| 2014 | 11.2 Billion INR | -96.46% |
| 2013 | 316.23 Billion INR | 2149.49% |
| 2012 | 14.05 Billion INR | -21.41% |
| 2011 | 17.88 Billion INR | 120.54% |
| 2010 | 8.11 Billion INR | -42.5% |
| 2009 | 14.1 Billion INR | 16.15% |
| 2008 | 12.14 Billion INR | 78.88% |
| 2007 | 6.78 Billion INR | -75.18% |
| 2006 | 27.35 Billion INR | 523.4% |
| 2005 | -6.46 Billion INR | -66.49% |
| 2004 | -3.88 Billion INR | 43.95% |
| 2003 | -6.92 Billion INR | -39.81% |
| 2002 | -4.95 Billion INR | -243.07% |
| 2001 | 3.46 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 6.5 Billion INR | -15.47% |
| 2024 Q3 | 12.5 Billion INR | 7869.57% |
| 2024 FY | 12.91 Billion INR | 67.85% |
| 2024 Q4 | 12.91 Billion INR | 3.23% |
| 2024 Q2 | -161 Million INR | -102.48% |
| 2023 Q3 | 11.4 Billion INR | 39.19% |
| 2023 Q1 | 18.64 Billion INR | -1.82% |
| 2023 FY | 7.69 Billion INR | -59.5% |
| 2023 Q4 | 7.69 Billion INR | -32.54% |
| 2023 Q2 | 8.19 Billion INR | -56.06% |
| 2022 Q1 | 25.2 Billion INR | 62.83% |
| 2022 FY | 18.99 Billion INR | 22.7% |
| 2022 Q2 | 20.29 Billion INR | -19.49% |
| 2022 Q4 | 18.99 Billion INR | 206.93% |
| 2022 Q3 | 6.18 Billion INR | -69.51% |
| 2021 Q2 | 23.54 Billion INR | -13.4% |
| 2021 FY | 15.47 Billion INR | -22.79% |
| 2021 Q1 | 27.18 Billion INR | 35.58% |
| 2021 Q4 | 15.47 Billion INR | -3.99% |
| 2021 Q3 | 16.12 Billion INR | -31.51% |
| 2020 Q1 | 32.32 Billion INR | -10.6% |
| 2020 FY | 20.04 Billion INR | -44.54% |
| 2020 Q4 | 20.04 Billion INR | 42.43% |
| 2020 Q3 | 14.07 Billion INR | -50.67% |
| 2020 Q2 | 28.53 Billion INR | -11.72% |
| 2019 Q3 | 42.12 Billion INR | -18.59% |
| 2019 FY | 36.15 Billion INR | -24.8% |
| 2019 Q1 | 52.08 Billion INR | 8.33% |
| 2019 Q2 | 51.74 Billion INR | -0.65% |
| 2019 Q4 | 36.15 Billion INR | -14.17% |
| 2018 Q3 | 52.9 Billion INR | 3.31% |
| 2018 FY | 48.07 Billion INR | 54.84% |
| 2018 Q1 | 47.63 Billion INR | 53.43% |
| 2018 Q2 | 51.2 Billion INR | 7.49% |
| 2018 Q4 | 48.07 Billion INR | -9.12% |
| 2017 FY | 31.04 Billion INR | 581.98% |
| 2017 Q4 | 31.04 Billion INR | -40.25% |
| 2017 Q3 | 51.96 Billion INR | -10.46% |
| 2017 Q2 | 58.03 Billion INR | 85.43% |
| 2017 Q1 | 31.29 Billion INR | 585.84% |
| 2016 Q4 | -6.44 Billion INR | -123.09% |
| 2016 FY | -6.44 Billion INR | -285.54% |
| 2016 Q2 | 30.39 Billion INR | -13.42% |
| 2016 Q3 | 27.89 Billion INR | -8.21% |
| 2016 Q1 | 35.1 Billion INR | 911.06% |
| 2015 Q3 | 33.37 Billion INR | 8.94% |
| 2015 Q2 | 30.63 Billion INR | -13.23% |
| 2015 Q4 | 3.47 Billion INR | -89.6% |
| 2015 Q1 | 35.3 Billion INR | 215.02% |
| 2015 FY | 3.47 Billion INR | -69.02% |
| 2014 FY | 11.2 Billion INR | -96.46% |
| 2014 Q1 | 34.91 Billion INR | -88.96% |
| 2014 Q2 | 37.7 Billion INR | 7.98% |
| 2014 Q3 | 28.11 Billion INR | -25.44% |
| 2014 Q4 | 11.2 Billion INR | -60.13% |
| 2013 Q2 | 27.92 Billion INR | 3.55% |
| 2013 FY | 316.23 Billion INR | 2149.49% |
| 2013 Q4 | 316.23 Billion INR | 1027.68% |
| 2013 Q3 | 28.04 Billion INR | 0.43% |
| 2013 Q1 | 26.96 Billion INR | 91.81% |
| 2012 Q3 | 21.91 Billion INR | -7.56% |
| 2012 Q1 | 18.47 Billion INR | 3.26% |
| 2012 FY | 14.05 Billion INR | -21.41% |
| 2012 Q4 | 14.05 Billion INR | -35.85% |
| 2012 Q2 | 23.7 Billion INR | 28.34% |
| 2011 Q2 | 8.29 Billion INR | 10.55% |
| 2011 FY | 17.88 Billion INR | 120.54% |
| 2011 Q1 | 7.5 Billion INR | -7.46% |
| 2011 Q4 | 17.88 Billion INR | 84.76% |
| 2011 Q3 | 9.68 Billion INR | 16.68% |
| 2010 Q4 | 8.11 Billion INR | 13.69% |
| 2010 Q1 | 9.92 Billion INR | -29.64% |
| 2010 Q2 | 8.51 Billion INR | -14.16% |
| 2010 Q3 | 7.13 Billion INR | -16.26% |
| 2010 FY | 8.11 Billion INR | -42.5% |
| 2009 Q1 | 15.12 Billion INR | 24.57% |
| 2009 Q2 | 17.06 Billion INR | 12.83% |
| 2009 FY | 14.1 Billion INR | 16.15% |
| 2009 Q4 | 14.1 Billion INR | -23.67% |
| 2009 Q3 | 18.48 Billion INR | 8.27% |
| 2008 Q3 | 10.83 Billion INR | 37.36% |
| 2008 Q2 | 7.89 Billion INR | 87.63% |
| 2008 Q1 | 4.2 Billion INR | -38.05% |
| 2008 FY | 12.14 Billion INR | 78.88% |
| 2008 Q4 | 12.14 Billion INR | 12.05% |
| 2007 Q2 | 27.39 Billion INR | -8.4% |
| 2007 Q3 | 11.28 Billion INR | -58.79% |
| 2007 Q4 | 6.78 Billion INR | -39.86% |
| 2007 FY | 6.78 Billion INR | -75.18% |
| 2007 Q1 | 29.9 Billion INR | 9.32% |
| 2006 Q1 | -6.41 Billion INR | 0.68% |
| 2006 Q3 | -4.28 Billion INR | 33.4% |
| 2006 Q2 | -6.42 Billion INR | -0.17% |
| 2006 Q4 | 27.35 Billion INR | 738.94% |
| 2006 FY | 27.35 Billion INR | 523.4% |
| 2005 Q1 | -1.75 Billion INR | 54.65% |
| 2005 FY | -6.46 Billion INR | -66.49% |
| 2005 Q2 | -4.06 Billion INR | -131.23% |
| 2005 Q3 | -3.65 Billion INR | 10.05% |
| 2005 Q4 | -6.46 Billion INR | -76.52% |
| 2004 Q3 | -5.59 Billion INR | 24.73% |
| 2004 Q4 | -3.88 Billion INR | 30.65% |
| 2004 Q2 | -7.43 Billion INR | -0.03% |
| 2004 FY | -3.88 Billion INR | 43.95% |
| 2004 Q1 | -7.43 Billion INR | -7.35% |
| 2003 FY | -6.92 Billion INR | -39.81% |
| 2003 Q2 | -6.3 Billion INR | -3.42% |
| 2003 Q1 | -6.09 Billion INR | -23.04% |
| 2003 Q4 | -6.92 Billion INR | -3.35% |
| 2003 Q3 | -6.69 Billion INR | -6.31% |
| 2002 Q1 | -2.61 Billion INR | 0.0% |
| 2002 FY | -4.95 Billion INR | -243.07% |
| 2002 Q2 | -2.72 Billion INR | -4.08% |
| 2002 Q3 | -3.83 Billion INR | -40.54% |
| 2002 Q4 | -4.95 Billion INR | -29.27% |
| 2001 FY | 3.46 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.65 Billion USD | -385.637% |
| Bausch Health Companies Inc. | 21.44 Billion USD | 39.774% |
| Catalent, Inc. | 4.69 Billion USD | -174.803% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -1586.21% |
| Elanco Animal Health Incorporated | 5.42 Billion USD | -138.159% |
| Perrigo Company plc | 3.32 Billion USD | -288.7% |
| Teva Pharmaceutical Industries Limited | 16.92 Billion USD | 23.714% |
| Zoetis Inc. | 4.76 Billion USD | -171.168% |